336191-57-2

Upstream product

• 539-74-2 Ethyl 3-bromopropionate 
• 505-66-8 1,4-Diazacycloheptane 
• 117009-97-9 benzyl 1,4-diazepane-1-carboxylate 
• 336191-56-1 4-(2-ethoxycarbonyl-ethyl)-[1,4]diazepane-1-carboxylic acid benzyl ester 

Downstream Products

• 336191-58-3 4-(2-ethoxycarbonyl-ethyl)-[1,4]diazepane-1-carboxylic acid 4-nitro-phenyl ester 
• 913643-57-9 3-(4-{3-[(R)-((2S,5R)-4-allyl-2,5-dimethyl-piperazin-1-yl)-(3-hydroxy-phenyl)-methyl]-benzoyl}-[1,4]diazepan-1-yl)-propionic acid ethyl ester 

Relevant academic research and scientific papers

COMPOSITIONS OF NOVEL OPIOID COMPOUNDS AND METHOD OF USE THEREOF

Diarylmethylpiperazine compounds are described, which are useful as mu and/or delta receptor opioid compounds, without central side effects. Pharmaceutical compositions containing such compounds are variously useful for peripheral or non-centrally mediated indications, including peripherally mediated and neuropathic pain, urogenital tract disorders, overactive bladder, urinary incontinence, sexual disorders, premature ejaculation, cough, lung edema, cardiac disorders, cardioprotection, gastro-intestinal disorders, diarrhea, irritable bowl syndrome, functional distention, immuno-modulation and anti-tumor activity.

Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 3: Synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes

The synthesis and biological activity of analogues containing spiro piperidinylpyridine and pyrrolidinylpyridine templates are described. The potent activity of these compounds as platelet aggregation inhibitors demonstrates the utility of the spiro structures as central template for nonpeptide RGD mimics.